Bristol-Myers Squibb Company company logo

# 1st Gen Model Bristol-Myers Squibb Company Pharmaceutical preparations

Subscribe >> Deal exit on
Oct. 24, 2017
Deal entry on
Oct. 24, 2017
1.14%Expected margin
66.67% successful of 27 deals
$63.75 Last close price
at 23-oct-2017


Model's trade recommendations 1.13% Return for period

-4.34% Annual return

$105.64B Market Cap

β 1.19  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.13%
52wk return 1.97%
52wk Range
Sortino ratio -0.69
Sharpe ratio -0.62
Norm. RMSE 0.19%
Downside risk 6.54%
Volatility 7.22%
  • 1.56 (2.42%) Div (Yield)
  • BUY Analysts consensus recommendation

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Bristol-Myers Squibb Company (BMY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BMY model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1636M
P/E 21.62
Shares Outstanding 1640M
% Held by Insiders 0.23%
% Held by Institutions 68.90%
EPS (last reported FY) $2.83
EPS (last reported Q) $0.74
EPS, estimated (last reported Q) $0.73
Total revenues $19 B
Net income $4 B